The primary catalyst is the VYD2311 data readout expected within weeks. Traders should monitor for the DECLARATION and LIBERTY results, which will determine the BLA filing path and the stock's near-term direction. The CEO change is a neutral administrative event.
Drug in focus
IVVD drug pipeline →PEMGARDA
▼ Bearish Named in this 8-K- Impact
- Phase
- Authorized (EUA)
- Time to market
- Already on market under EUA since March 2024. EUA terminates June 29, 2027 unless converted to full BLA approval. BLA pathway being explored.
- Next catalyst
- None dated
What to watchThe EUA termination notice (effective June 2027) puts a clock on PEMGARDA's revenue stream and makes BLA conversion or VYD2311 success existential for Invivyd. Watch for VYD2311 Phase 3 LIBERTY/DECLARATION topline data expected Q3 2026, that will be the next major price catalyst, not a PEMGARDA event. The stock has substantial institutional support but faces significant regulatory overhang.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 1 $0.8800entry
- T+1 · 3mo ago −8.64%α −9.08% · $0.8040
- T+5 · 2mo ago −9.40%α −9.48% · $0.7973
- T+20 · 7w ago −4.08%α −5.26% · $0.8441
- T+53 · todayOpen
- T+60 · in 8d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Invivyd appointed Chairman Marc Elia as CEO, replacing the CFO who had been serving as principal executive officer. The filing also announced top-line data from the VYD2311 Phase 3 DECLARATION and LIBERTY studies is expected around the end of Q3 2026, with the company planning to submit a BLA for either traditional or accelerated approval. This is a routine CEO appointment combined with a near-term binary catalyst from pivotal clinical readouts.
Key Facts
- Marc Elia appointed CEO effective August 30, 2026; he retains Chairman title.
- Elia receives $750,000 base salary, 70% target bonus, $500,000 sign-on bonus, and an option for 10,700,000 shares.
- Top-line data from VYD2311 DECLARATION and LIBERTY studies expected around end of Q3 2026.
- Company plans to submit a BLA for VYD2311 for either traditional or accelerated approval after data readout.
- Ian Sheffield appointed to the Board as an independent director; Ajay Royan appointed Lead Independent Director.
Financial Impact
CEO compensation package includes $750K salary, $500K sign-on bonus, and 10.7M share option grant. VYD2311 BLA submission is a binary catalyst with no disclosed financial terms.
Risk Factors
- VYD2311 clinical data may fail to meet statistical endpoints, delaying or preventing BLA submission.
- Potential dilution from the 10.7M share option grant to the new CEO.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-377493 |
| Document: ivvd-20260830.htm | 0001193125-26-377493 |
| Document: ivvd-ex99_1.htm | 0001193125-26-377493 |
| Document: 0001193125-26-377493-index-headers.html | 0001193125-26-377493 |
| Document: 0001193125-26-377493-index.html | 0001193125-26-377493 |
| Document: 0001193125-26-377493.txt | 0001193125-26-377493 |
Track record
19 reports on IVVD
3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Viewing Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers